Stealth BioTherapeutics Corp. ADS - ADR Financials

$0.32

$0.00 (0.00%)

As on 16-Nov-2022 09:30EDT

Market cap

$24 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

36.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	--	--	--	21.09	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Operating Expenses	48.30	46.30	48.67	66.92	75.28	79.72
Operating Profit (EBIT)	-48.30	-46.30	-48.67	-45.83	-75.28	-79.72
Other Income	--	--	--	--	--	--
Profit before Tax	-52.97	-52.53	-57.46	-71.73	-96.71	-82.91
Provision for Tax	--	--	--	--	--	--
Profit after Tax (Net Income)	-52.97	-52.53	-57.46	-71.73	-96.71	-82.91
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-44.84	-52.53	-57.46	-71.73	-96.71	-82.91

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	-52.32	-45.30	-10.37	17.27	-386.71	-291.29
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	79.34	84.69	25.17	1.53	361.62	273.85
Current Liabilities	9.89	10.83	21.05	33.95	40.61	24.59
Total Liabilities	46.80	50.23	35.85	52.74	15.52	7.15

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	0.52	0.62	0.81	0.35	2.23	1.23
Current Assets	36.40	49.60	35.04	52.40	13.29	5.92
Total Assets	46.80	50.23	35.85	52.74	15.52	7.15
Total Debt*	13.78	13.66	9.00	16.24	122.04	64.05
Net Current Assets	26.51	38.77	13.99	18.45	-27.32	-18.67

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-44.97	-53.54	-47.98	-72.08	-69.84
Cash Flow from Investing Activities	--	0.18	-0.06	-0.13	-0.01	-0.17
Cash from Financing Activities	--	59.14	35.62	88.03	78.83	64.42
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	-0.93	-0.92	-1.25	-2.31	-16.12	--
Cash EPS ($)	--	-0.92	-1.24	-2.30	-16.07	--
Adjusted Book Value ($)	--	--	--	0.56	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.79	-1.16	-1.55	-12.01	--
Free Cash Flow per Share ($)	--	-0.79	-1.16	-1.55	-12.01	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	318.24	-357.58	62.06	39.32	37.94
ROE (%)	--	188.72	-1,666.63	38.83	28.53	33.09
ROA (%)	-108.34	-122.05	-129.71	-210.14	-852.93	-809.78
EBIT Margin (%)	--	--	--	-308.54	--	--
Net Margin (%)	--	--	--	-340.15	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	--	--	-1.00	--	--	--
EBIT Growth (%)	33.04	4.60	25.41	13.35	5.75	-30.49
Net Profit Growth (%)	-6.79	8.58	19.90	25.83	-16.65	-35.81
EPS Growth (%)	9.47	0.26	0.46	0.86	--	--
Book Value Growth (%)	-289.81	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	-0.90	-1.20	-1.41	--	--
Price / Book Value	36.57	-1.04	-6.63	5.85	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.07	-0.30	-0.93	-1.03	--	--
Close Price ($)	0.70	0.83	1.50	3.26	--	--
High Price ($)	2.45	2.58	5.00	20.99	--	--
Low Price ($)	0.47	0.68	0.90	3.15	--	--
Market Cap ($ Cr)	23.54	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	-0.26	-0.30	-0.87	0.94	-0.32	-0.22
Short term debt to equity ratio	--	--	--	0.85	-0.02	-0.01
Current Ratio	3.68	4.58	1.66	1.54	0.33	0.24
Quick Ratio	3.68	--	--	--	--	--
Interest Coverage	-34.72	-37.28	-26.84	-9.76	-3.52	-24.27

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	0.62	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.